Table 2. Distribution of metastatic lesions and reasons for performing SRT treatment.

Patient identification number	Oligometastatic disease ab initio	Reasons for first-line SRT	Distribution of lesions at first SRT	Total number of lesions
1	No	NA	3 lung, 2 liver	5
2	Yes	Refusal of metastasectomies	3 lung	3
3	Yes	Refusal of metastasectomies	1 lung, 2 liverB	3
4	Yes	Comorbidities	3 lung, 2 abdominal LN	5
5	Yes	Refusal of metastasectomies	2 liver	2
6	No	NA	2 lung	2
7	No	NA	4 lung	4
8	Yes	Refusal of metastasectomies	2 lung	2
9	Yes	Refusal of metastasectomies	3 liver	3
10	No	NA	2 lung, 2 liver	4
11	Yes	Refusal of metastasectomies	3 lung	3
12	No	NA	3 lung, 2 abdominal LN	5
13	Yes	Comorbidities	6 lung	6
14	Yes	Refusal of metastasectomies	2 lung, 1 abdominal LN	3
15	No	NA	2 liver, 2 abdominal LN	4
16	Yes	Refusal of metastasectomies	3 liverB	3
17	Yes	Refusal of metastasectomies	1 lung	1
18	No	NA	2 lung	2
19	Yes	Comorbidities	3 liver, 2 abdominal LN	5
20	Yes	Comorbidities	4 liverB	4
21	Yes	Refusal of metastasectomies	2 lung	2
22	No	NA	3 lung, 1 abdominal LN	4
23	No	NA	5 lung	5
24	No	NA	4 lung	4
25	Yes	Comorbidities	2 lung, 1 abdominal LN	3
26	Yes	Comorbidities	3 liver, 2 abdominal LN	5
27	Yes	Refusal of metastasectomies	2 lung	2
28	No	NA	4 lung, 3 liver	7
29	Yes	Comorbidities	2 lung, 1 liver	3
30	Yes	Refusal of metastasectomies	3 liverB	3
31	Yes	Comorbidities	5 liver	5
32	Yes	Comorbidities	4 lung, 2 liver	6
33	No	NA	3 lung	3
34	Yes	Refusal of metastasectomies	1 lung, 1 liver	2
35	Yes	Comorbidities	6 lung	6
36	Yes	Refusal of metastasectomies	3 lung	3
37	No	NA	2 lung	2
38	No	NA	5 lung, 2 abdominal LNB	7
39	Yes	Refusal of metastasectomies	2 lung	2
40	Yes	Comorbidities	3 lung, 1 abdominal LN	4
41	No	NA	5 lung	5
42	Yes	Refusal of metastasectomies	1 lung	1
43	Yes	Comorbidities	3 lung, 3 liver	6
44	No	NA	3 lung	3
45	No	NA	2 lung	2
46	Yes	Comorbidities	3 liverB	3
47	No	NA	4 lung, 3 liver	7

NA: Not Applicable, in these cases SRT was performed after chemotherapy for poly-metastatic disease on “residual” masses.

^BThese patients experienced progressive disease at first-line chemotherapy.